LLY vs VST: Which Is the Better Buy?

Side-by-side comparison of Eli Lilly and Company and Vistra Corp. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-08-06.
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction Grade A High Quality
VS
Vistra Corp. · Utilities
$140.58
+20.9% upside to fair value
Med Conviction Grade B
QuantHub Verdict
LLY has more upside to fair value (+31.7%). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric LLY VST
Current Price $1,179.09 $140.58
Fair Value Estimate $1,552.32 $170.00
Upside to Fair Value +31.7% +20.9%
Market Cap $1,110.4B $47.4B
Forward P/E 15.4x
EV / EBITDA 34.3x 9.3x
Price / Sales 14.6x 2.9x
Price / FCF 77.7x 42.5x
Revenue Growth YoY +55.5% +20.0%
Gross Margin 83.5% 12.7%
Operating Margin 45.9% 2.1%
Return on Equity 101.3% 35.0%
Dividend Yield 0.55% 0.65%
FCF Yield 1.29% 2.4%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
LLY — Eli Lilly and Company
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
VST — Vistra Corp.
Vistra is an integrated merchant power producer and retail electricity supplier with roughly 38,700 MW of generation across natural gas, nuclear, coal, solar and battery storage, plus a roughly 4.3 million customer retail book (TXU and affiliated brands) across 20 states. The 2024 Energy Harbor deal made it the second-largest nuclear operator in the US, and that nuclear and gas fleet is now centr…
Accumulation Zones
Metric LLY VST
Zone Low $1,164.24 $128.00
Zone High $1,319.47 $145.00
In Buy Zone? Yes Yes
← LLY Research    VST Research →    All Research